NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
Clinical Trials
10 trialsNCT00667069 2025-06-05
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
UNICANCER
Phase 3 Completed
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT00033631 2023-01-18
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00331773 2023-01-18
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00002602 2020-01-10
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00528866 2019-04-24
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00551525 2017-07-25
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00949962 2014-07-04
Post-operative or Early Salvage XRT and ADT for High Risk PCa
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated